Neurology · AntidepressantRegulatory Approvalcommercialnear-term

FDA Grants Approval for Doxepin Hydrochloride ANDA213919 by Sun Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sun Pharma21 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:32:43 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Sun Pharma's generic Doxepin Hydrochloride presents a significant shift in the competitive landscape for this therapeutic area. Portfolio teams must evaluate the implications for pricing and market share of existing branded products to strategize effectively. Regulatory context from FDA (FDA AP — DOXEPIN HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on sales forecasts and competitive positioning of existing Doxepin products. The strongest clinical anchor is Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata (ClinicalTrials.gov), entity match (sun pharma). In Neurology · Antidepressant, 8 regulatory and 2 competitive items passed relevance filtering for Sun Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases. This approval allows Sun Pharma to enter the market with a generic alternative to Doxepin, potentially impacting pricing and market share of existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DOXEPIN HYDROCHLORIDE (ORIG) (FDA). Entity match (sun pharma); Regulatory pathway relevance (nda). While the approval itself is a routine regulatory event, it indicates a shift in market dynamics that may require ongoing compliance monitoring for existing products.

Key Risks

Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic competitor is likely to drive down prices and erode market share for existing branded Doxepin products, potentially impacting revenue streams significantly.
Lead sponsor: Sichuan Credit Pharmaceutical Co., Ltd.. An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
Upside for Sun Pharma may improve if Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Genentech, Inc.. The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Portfolio teams should assess the impact of this generic entry on sales forecasts and competitive positioning of existing Doxepin products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and pricing strategies from Sun Pharma and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DOXEPIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sun pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
ClinicalTrials.govhigh relevance
Entity match (sun pharma)
FDA document
View source
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases
Humanexa Signalsmedium relevance
Moderate corpus alignment

Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
Doxepin Hydrochloride

Commercial impact

high

The entry of a generic competitor is likely to drive down prices and erode market share for existing branded Doxepin products, potentially impacting revenue streams significantly.

Regulatory impact

medium

While the approval itself is a routine regulatory event, it indicates a shift in market dynamics that may require ongoing compliance monitoring for existing products.

What to watch

Monitor market entry timing and pricing strategies from Sun Pharma and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.